Cal Pharma Revenue and Competitors

Whittier, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cal Pharma's estimated annual revenue is currently $1.1M per year.(i)
  • Cal Pharma's estimated revenue per employee is $155,000

Employee Data

  • Cal Pharma has 7 Employees.(i)
  • Cal Pharma grew their employee count by 0% last year.

Cal Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Cal Pharma?

ABOUT CAL PHARMA — Cal Pharma is a leading therapeutic and cosmetic skincare company. We are setting new standards in multifunctional sun protection with our popular SPF Rx brand, one of eight dynamic skin and hair care brands that we develop, market and sell across medical, professional and corporate/government channels. All of our products are manufactured in California, in an FDA approved facility under cGMP guidelines. Cal Pharma has over 60 years of combined experience backed by an R&D team of cosmetic chemists, a licensed pharmacist, and a certified dermatologist. All Cal Pharma products are made in the USA. Cal Pharma is committed to utilizing innovative and functional ingredients to create products that have been formulated in the most effective delivery systems to provide successful results. Areas of expertise include anti aging , acne, sun care, pain formulations and specialty hair care products. More information can be found at http://www.cal-pharma.com, or by calling Cal Pharma corporate offices at 1 (888) 551-7778.

keywords:N/A

N/A

Total Funding

7

Number of Employees

$1.1M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M8-81%N/A
#2
$0.6M80%N/A
#3
$0.7M90%N/A
#4
$0.9M10-76%N/A
#5
$75M1427%N/A